Every time Rosalie publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ...

Maybe you’re a closet Clojure or Scala developer, or perhaps you’ve worked with LISP in the past. If so, there’s a good chance you’ve used a REPL as a part of your daily routine. REPL, or ...

Today’s entrepreneur is Faris Masad, co-founder and CTO of Repl.it. Repl.it’s platform lets users start coding in the programming languages they choose, build and deploy apps right from their browsers ...

Amjad Masad is the co-founder and CEO of Repl.it. Repl.it’s platform lets users to start coding in the programming languages they choose, build and deploy apps right from their browsers. Amjad has ...

Replimune (REPL) announced that it has submitted a biologics license application, or BLA, to the FDA for RP1 in combination with nivolumab for the treatment of adult patients with advanced melanoma ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...